ACAndrew H. Coles

Andrew H. Coles

*This is an algorithmically generated author record based on publicly available information.

Andrew H. Coles has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Anastasia Khvorova

    RNA Therapeutics Institute, UMass Chan Medical School, Worcester, USA

    4 shared publications
  • Dimas Echeverria

    RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA

    2 shared publications
  • Dimas Echeverria

    RNA Therapeutics Institute, University of Massachusetts Chan School of Medicine , Worcester, Massachusetts

    2 shared publications
  • Maire F. Osborn

    RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA

    2 shared publications
  • Socheata Ly

    Morningside Graduate School of Biomedical Sciences, T.H. Chan School of Medicine, Interdisciplinary Graduate Program, RNA Therapeutics Institute, Program in Molecular Medicine, Systems Biology, Biochemistry and Molecular Biotechnology, Microbiology and Physiological Systems, MD/PhD Program, University of Massachusetts Chan Medical School , Worcester , MA 01655

    2 shared publications
  • Annabelle Biscans

    RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA

    1 shared publication

Latest Publications

  • Open Access

    Figure S1, Table S1, Table S2, Supplementary Methods from Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs

    by Maire F. Osborn, Andrew H. Coles, Diane Golebiowski, Dimas Echeverria, Michael P. Moazami, Jonathan K. Watts, Miguel Sena-Esteves, Anastasia Khvorova

  • Open Access

    Mutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains

    by Socheata Ly, Marie-Cécile Didiot, Chantal M Ferguson, Andrew H Coles, Rachael Miller, Kathryn Chase, Dimas Echeverria, Feng Wang, Ghazaleh Sadri-Vakili, Neil Aronin, et al.

    Mutant messenger RNA (mRNA) and protein contribute to the clinical manifestation of many repeat-associated neurological disorders, with the presence of nuclear RNA clusters being a common pathological feature. Yet, investigations into Huntington’s disease—caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene—have primarily focused on toxic protein gain-of-function as the primary disease-causing feature. To date, mutant HTT mRNA has not been identified as an in vivo hallmark of Huntington’s disease. Here, we report that, in two Huntington’s disease mouse models (YAC128 and BACHD-97Q-ΔN17), mutant HTT mRNA is retained in the nucleus. Widespread formation of large mRNA clusters (∼0.6–5 µm3) occurred in 50–75% of striatal and cortical neurons. Cluster formation was independent of age and driven by expanded repeats. Clusters associate with chromosomal transcriptional sites and quantitatively co-localize with the aberrantly processed N-terminal exon 1-intron 1 mRNA isoform, HTT1a. HTT1a mRNA clusters are observed in a subset of neurons from human Huntington’s disease post-mortem brain and are likely caused by somatic expansion of repeats. In YAC128 mice, clusters, but not individual HTT mRNA, are resistant to antisense oligonucleotide treatment. Our findings identify mutant HTT/HTT1a mRNA clustering as an early, robust molecular signature of Huntington’s disease, providing in vivo evidence that Huntington’s disease is a repeat expansion disease with mRNA involvement.


  • Open Access

    Diverse lipid conjugates for functional extra-hepatic siRNA deliveryin vivo

    by Annabelle Biscans, Andrew Coles, Reka Haraszti, Dimas Echeverria, Matthew Hassler, Maire Osborn, Anastasia Khvorova

    Small interfering RNA (siRNA)-based therapies are proving to be efficient for treating liver-associated disorders. However, extra-hepatic delivery remains challenging, limiting therapeutic siRNA utility. We synthesized a panel of fifteen lipid-conjugated siRNAs and systematically evaluated the impact of conjugate on siRNA tissue distribution and efficacy. Generally, conjugate hydrophobicity defines the degree of clearance and the liver-to-kidney distribution profile. In addition to primary clearance tissues, several conjugates achieve significant siRNA accumulation in muscle, lung, heart, adrenal glands and fat. Oligonucleotide distribution to extra-hepatic tissues with some conjugates was significantly higher than with cholesterol, a well studied conjugate, suggesting that altering conjugate structure can enhance extra-hepatic delivery. These conjugated siRNAs enable functional gene silencing in lung, muscle, fat, heart and adrenal gland. Required levels for productive silencing vary (5–200 μg/g) per tissue, suggesting that the chemical nature of conjugates impacts tissue-dependent cellular/intracellular trafficking mechanisms. The collection of conjugated siRNA described here enables functional gene modulation in vivo in several extra-hepatic tissues opening these tissues for gene expression modulation. A systemic evaluation of a panel of conjugated siRNA, as reported here, has not previously been investigated and shows that chemical engineering of lipid siRNAs is essential to advance the RNA therapeutic field.


  • Open Access

    Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways

    by Maire F Osborn, Andrew H Coles, Annabelle Biscans, Reka A Haraszti, Loic Roux, Sarah Davis, Socheata Ly, Dimas Echeverria, Matthew R Hassler, Bruno M D C Godinho, et al.

    Efficient delivery of therapeutic RNA beyond the liver is the fundamental obstacle preventing its clinical utility. Lipid conjugation increases plasma half-life and enhances tissue accumulation and cellular uptake of small interfering RNAs (siRNAs). However, the mechanism relating lipid hydrophobicity, structure, and siRNA pharmacokinetics is unclear. Here, using a diverse panel of biologically occurring lipids, we show that lipid conjugation directly modulates siRNA hydrophobicity. When administered in vivo, highly hydrophobic lipid-siRNAs preferentially and spontaneously associate with circulating low-density lipoprotein (LDL), while less lipophilic lipid-siRNAs bind to high-density lipoprotein (HDL). Lipid-siRNAs are targeted to lipoprotein receptor-enriched tissues, eliciting significant mRNA silencing in liver (65%), adrenal gland (37%), ovary (35%), and kidney (78%). Interestingly, siRNA internalization may not be completely driven by lipoprotein endocytosis, but the extent of siRNA phosphorothioate modifications may also be a factor. Although biomimetic lipoprotein nanoparticles have been explored for the enhancement of siRNA delivery, our findings suggest that hydrophobic modifications can be leveraged to incorporate therapeutic siRNA into endogenous lipid transport pathways without the requirement for synthetic formulation.